Unlocking Early Detection: A New Era in Colorectal Cancer Screening
In a significant development, the American Cancer Society has expanded its screening guidelines for colorectal cancers, introducing a blood test as a viable option. This move, a first for the organization, aims to bridge the gap in screening rates, especially among those who hesitate or are unable to undergo traditional invasive procedures.
The Evolution of Screening Options
Colonoscopies, while effective, are not everyone's preferred choice due to their invasive nature and the need for anesthesia. Other visual exams and stool-based tests, though recommended, can be off-putting for some. The new guideline addresses this by offering a less invasive alternative - a blood test.
Shielding Against Colorectal Cancer
The recommended blood test, known as the Shield test, developed by Guardant Health, has gained FDA approval in 2024. This test is now an option for adults aged 45 and above at average risk, especially those who have declined or cannot complete visual or stool-based exams.
A Step Towards Widespread Screening
Despite not being the 'first choice' due to its lower sensitivity in detecting precancerous polyps, the blood test is seen as a crucial step towards increasing screening rates. Dr. William Dahut, the American Cancer Society's chief scientific officer, believes it's the right option for those who cannot or will not undergo more invasive procedures.
The Impact of Early Detection
Early screening can significantly improve survival rates. More than 90% of people who detect colorectal cancer at stages I and II survive for at least five years. However, when cancer is found at a later stage, it becomes more challenging to treat, emphasizing the importance of early detection.
Preventive Measures
Almost all colorectal cancers begin as precancerous polyps. Visual exams like colonoscopies can identify and remove these polyps before they become cancerous. Stool tests also play a crucial role in detecting precancerous signs, and a positive result often leads to a colonoscopy, offering an opportunity for prevention.
A Realistic Approach
Dr. Ursina Teitelbaum, a gastrointestinal oncology professor, praises the updated guideline as "very forward-thinking and reality-based." She acknowledges that while blood-based testing is not perfect, it broadens the scope of screening, especially for younger, vulnerable populations.
The Future of Blood-Based Testing
Dr. Scott Kopetz, a gastrointestinal oncologist, believes that the Shield test is just the beginning. He anticipates more blood-based tests in the future, with improved performance and reduced access barriers. However, he emphasizes that for now, blood-based screening should be reserved for those who cannot or will not undergo other recommended methods.
Conclusion
The inclusion of a blood test in colorectal cancer screening guidelines marks a significant shift towards more accessible and less invasive detection methods. While it may not be the primary choice, it offers a crucial alternative for those hesitant about traditional screening options. This development underscores the importance of early detection and prevention in the fight against colorectal cancer.
